THE SCAVENGER CELL PATHWAY FOR LIPOPROTEIN DEGRADATION - SPECIFICITY OF THE BINDING-SITE THAT MEDIATES THE UPTAKE OF NEGATIVELY-CHARGED LDL BY MACROPHAGES
THE SCAVENGER CELL PATHWAY FOR LIPOPROTEIN DEGRADATION - SPECIFICITY OF THE BINDING-SITE THAT MEDIATES THE UPTAKE OF NEGATIVELY-CHARGED LDL BY MACROPHAGES
复制标题
DOI:
10.1002/jss.400130107
复制
发表时间:
1980-01-01
期刊:
影响因子:
--
通讯作者:
GOLDSTEIN, JL
中科院分区:
文献类型:
--
作者:
BROWN, MS;BASU, SK;GOLDSTEIN, JL
Macrophages isolated from a variety of organs in several animal species [including mice and rats] exhibit high affinity binding sites that recognize chemically modified proteins. One of these binding sites recognizes human plasma low density lipoprotein (LDL) in which the positive charges on the .epsilon.-amino groups of lysine have been removed or neutralized by chemical modification, thus giving the protein an enhanced negative charge. Effective treatments include reaction of LDL with organic acid anhydrides (acetylation or maleylation) and reaction with aldehydes, such as treatment with malondialdehyde. After the negatively-charged LDL binds to the surface receptor sites, it is rapidly internalized by the macrophages by endocytosis and hydrolyzed in lysosomes. The liberated cholesterol is reesterified in the cytoplasm, producing massive cholesteryl ester deposition. The binding site for negatively-charged LDL has been demonstrated so far only on macrophages and other scavenger cells. It is not expressed in cultured fibroblasts, smooth muscle cells, lymphocytes or adrenal cells. In addition to its affinity for acetylated LDL and malondialdehyde-treated LDL, the macrophage site binds a variety of polyanions. It exhibits a particularly high affinity for certain sulfated polysaccharides (dextran sulfate and fucoidin), certain polynucleotides (polyinosinic acid and polyguanylic acid), polyvinyl sulfate and maleylated albumin. The site that binds negatively-charged LDL may be responsible for the massive accumulation of cholesteryl esters that occurs in macrophages and other scavenger cells in patients with high levels of circulating plasma LDL. [Applicability of this study to familial hypercholesterolemia and atherosclerosis was discussed].